Onconova Therapeutics Inc. Announces Presentation of Oral Rigosertib Safety and Activity Data in Lower Risk Myelodysplastic Syndromes at the 2013 American Society of Clinical Oncology Annual Meeting
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, today announced that new safety and clinical activity data from its Phase 2 ONTARGET study will be presented on Saturday, June 1 during the American Society of Clinical Oncology Annual Meeting May 31 – June 4, 2013 in Chicago, Illinois. The ONTARGET trial is designed to evaluate oral rigosertib as a single agent in transfusion-dependent lower risk myelodysplastic syndrome patients.
Help employers find you! Check out all the jobs and post your resume.
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, today announced that new safety and clinical activity data from its Phase 2 ONTARGET study will be presented on Saturday, June 1 during the American Society of Clinical Oncology Annual Meeting May 31 – June 4, 2013 in Chicago, Illinois. The ONTARGET trial is designed to evaluate oral rigosertib as a single agent in transfusion-dependent lower risk myelodysplastic syndrome patients.
Help employers find you! Check out all the jobs and post your resume.